Hair Growth Treatment
This week, there is interesting news for those with alopecia areata. Nektar Therapeutics has announced that it will launch a Phase 2b trial for its drug rezpegaldesleukin (REZPEG), which will be assessed in individuals suffering from severe to very severe alopecia areata (AA). Nektar Therapeutics is a biotech firm with several indications in the pipeline…
Read More
Pelage Pharma Presents Data From its Phase 1 Clinical Study: Update (03/09/2024) On March 9th, Pelage Pharma unveiled data at the AAD 2024 Annual Meeting, showcasing PP405. Through translational and Phase 1 clinical studies, PP405 demonstrated its ability to reactivate dormant hair follicle stem cells, triggering hair regrowth. Pelage Pharma has provided an overview of…
Read More
Earlier this month, Stemson Therapeutics announced its hair follicle regeneration research advancement. What is Stemson Therapeutics Working On? The company is focused on developing a cell therapy solution for hair loss. They use autologous (meaning from the self) induced pluripotent stem cells (iPSCs) to engineer follicular units to form new hair follicles. These will be…
Read More
We interviewed skin and hair biology researcher Xunwei Wu about his ongoing research in hair follicle regeneration. Let’s look at what researchers are working on for the future of hair regrowth. Who is Xunwei Wu? Xunwei Wu is a researcher who has worked in dermatology (specifically skin biology) for more than 20 years. In the…
Read More
A team of researchers led by Chunming Wang from the University of Macau, in collaboration with scientists from the University of Nanjing and Wenzhou Medical University, have conducted a study on the use of an oligosaccharide biomaterial (OG6) to stimulate hair growth in mice. The study is based on understanding the crucial role of local…
Read More
Interesting news from Technoderma Medicines Inc. about their Phase 2a trial. TDM-105795: Positive Results Observed Compared to Baseline Technoderma Medicines Inc. has completed a Phase 2a clinical trial for TDM-105795, “A Randomized, Double-Blind, Vehicle Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects with Androgenetic Alopecia.” TDM-105795 is…
Read More
The Aesthetic Tech Forum 2024 is underway (January 25th and 26th) and features a session titled “Revitalizing Radiance: Advances in Hair Restoration“. Panelists include: Wajdie Ahmad, Executive Chairman & COO of Amplifica Holdings Group, Inc.; Amplifica is a biopharmaceutical company with several treatments in the pipeline targeted towards androgenic alopecia (AMP-303, AMP-203, and AMP-601). Drew…
Read More
Another Korean company has emerged with an exciting and potentially world-first approach to developing new hair loss therapies using hair follicle organoids. Kangstem Biotech Kangstem Biotech was established in 2010 and has several stem cell therapies in the pipeline for atopic dermatitis, rheumatoid arthritis, and osteoarthritis. Recently, Kangstem Biotech announced an expansion into hair loss…
Read More
Hair Cloning Research Expanding There has been no shortage of hair cloning news in the world of late, which is a good thing. In fact, three out of my four recent articles featured different hair cloning treatment modalities. This article will discuss more, and you can expect even more hair cloning news coming soon to…
Read More
Published on: Oct 7, 2020 at 20:04
Read More